Thalidomide-PEG2-C2-NH2 TFA

Cat. No.: HY-129703A

CAS No.: 2097509-36-7

Molecular Formula: $C_{21}H_{25}F_3N_4O_8$

Molecular Weight: 518.44

Target: E3 Ligase Ligand-Linker Conjugates; Apoptosis; Autophagy

Pathway: PROTAC; Apoptosis; Autophagy

Storage: -20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (192.89 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.9289 mL	9.6443 mL	19.2886 mL
	5 mM	0.3858 mL	1.9289 mL	3.8577 mL
	10 mM	0.1929 mL	0.9644 mL	1.9289 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Thalidomide-PEG2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology[1].

IC_{50} & Target

Cereblon

In Vitro

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Wang Z, et al. Proteolysis Targeting Chimeras for the Selective Degradation of Mcl-1/Bcl-2 Derived from Nonselective Target Binding Ligands. J Med Chem. 2019 Sep 12;62(17):8152-8163.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA